actabiomedicaActa Biomedica ScientificaActa Biomedica Scientifica2541-94202587-9596Scientific Centre for Family Health and Human Reproduction Problemsactabiomedica-802Research ArticleОБЗОРЫ ЛИТЕРАТУРЫREVIEWS OF LITERATUREМОЛЕКУЛЯРНО-ГЕНЕТИЧЕСКИЙ ПОДХОД К ОПТИМИЗАЦИИ СОВРЕМЕННОЙ АНТИАГРЕГАНТНОЙ ТЕРАПИИMOLECULAR-GENETIC APPROACH FOR OPTIMIZATION OF MODERN ANTIAGGREGANT THERAPYКнауэрН. Ю.KnauerN. YU.noemail@neicon.ruЛифшицГ. И.LifshitsG. I.noemail@neicon.ruФГБОУ ВПО «Новосибирский национальный исследовательский государственный университет»Novosibirsk National Research State UniversityИнститут химической биологии и фундаментальной медицины СО РАН, НовосибирскInstitute of Chemical Biology and Fundamental Medicine SB RAS20122804201202(1)143152Copyright © Кнауэр Н.Ю., Лифшиц Г.И., 20122012Кнауэр Н.Ю., Лифшиц Г.И.Knauer N.Y., Lifshits G.I.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.actabiomedica.ru/jour/article/view/802

В обзоре рассмотрены точки приложения антиагрегантной терапии клопидогрелем и факторы, влияющие на ее исход. Особое внимание уделено применению персонализированного подхода для оптимизации терапии клопидогрелем., обсуждены данные клинических исследований.

The targets of application of antiaggregant therapy by clopidogrel and the factors that influence its outcome were presented, in this review. Special attention was given to the application of personalized, approach for the optimization of clopidogrel therapy. The data of clinical investigations were discussed.

клопидогрельперсонализированная терапияMDR1CYP2C19clopidogrelpersonalized therapyMDR1CYP2C19ReferencesГрацианский Н.А. Национальные рекомендации по лечению ОКС без стойкого подъема ST на ЭКГ // Кардиоваскулярная терапия и профилактика. - 2006. - Вып. 8, № 5. - С. 411-440.Грацианский Н.А. Национальные рекомендации по лечению ОКС без стойкого подъема ST на ЭКГ // Кардиоваскулярная терапия и профилактика. - 2006. - Вып. 8, № 5. - С. 411-440.Диагностика и лечение фибрилляции предсердий / А.Л. Сыркин, В.А. Сулимов, И.Г. Фомина [и др.] // Кардиоваскулярная терапия и профилактика. - 2005. - Вып. 4, № 4. - P. 475-508.Диагностика и лечение фибрилляции предсердий / А.Л. Сыркин, В.А. Сулимов, И.Г. Фомина [и др.] // Кардиоваскулярная терапия и профилактика. - 2005. - Вып. 4, № 4. - P. 475-508.Национальные рекомендации по диагностике и лечению стабильной стенокардии / Р.С. Акчурин, Ю.А. Васюк, Ю.А. Карпов [и др.]. - М., 2009.Национальные рекомендации по диагностике и лечению стабильной стенокардии / Р.С. Акчурин, Ю.А. Васюк, Ю.А. Карпов [и др.]. - М., 2009.Ahmad T., Voora D., Becker R.C. The pharmacogenetics of antiplatelet agents: towards personalized therapy? // Nat. Rev. Cardiol. - 2011. - Vol. 8. -N 10. - P. 560-571.Ahmad T., Voora D., Becker R.C. The pharmacogenetics of antiplatelet agents: towards personalized therapy? // Nat. Rev. Cardiol. - 2011. - Vol. 8. -N 10. - P. 560-571.Ambudkar S.V., Kim I.W., Sauna Z.E. The power of the pump: mechanisms of action of P-glycoprotein (ABCB1) // Eur. J. Pharm. Sci. - 2006. - Vol. 27, N 5. - P. 392-400.Ambudkar S.V., Kim I.W., Sauna Z.E. The power of the pump: mechanisms of action of P-glycoprotein (ABCB1) // Eur. J. Pharm. Sci. - 2006. - Vol. 27, N 5. - P. 392-400.Angiolillo D.J., Ferreiro J.L. Platelet adenosine diphosphate P2Y12 receptor antagonism: benefits and limitations of current treatment strategies and future directions // Rev. Esp. Cardiol. - 2010. - Vol. 63, N 1. - P. 60-76.Angiolillo D.J., Ferreiro J.L. Platelet adenosine diphosphate P2Y12 receptor antagonism: benefits and limitations of current treatment strategies and future directions // Rev. Esp. Cardiol. - 2010. - Vol. 63, N 1. - P. 60-76.Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy / A.R. Shuldiner, J.R. O'Connell, K.P. Bliden [et al.] // J. Am. Med. Assoc. - 2009. -Vol. 302, N 8. - P. 849-857.Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy / A.R. Shuldiner, J.R. O'Connell, K.P. Bliden [et al.] // J. Am. Med. Assoc. - 2009. -Vol. 302, N 8. - P. 849-857.Chua D., Legal M., Shalansky S.J. Clopidogrel plus aspirin in atrial fibrillation // N. Engl. J. Med. - 2009. - Vol. 361, N 13. - P. 1312-1313.Chua D., Legal M., Shalansky S.J. Clopidogrel plus aspirin in atrial fibrillation // N. Engl. J. Med. - 2009. - Vol. 361, N 13. - P. 1312-1313.Clopidogrel, haemorrhage and haematological disorders // WHO Drug Information. - 2004.Clopidogrel, haemorrhage and haematological disorders // WHO Drug Information. - 2004.Clopidogrel: new use / Ed. C. Encrenaz // WHO Drug Information. - 2006. - P. 199.Clopidogrel: new use / Ed. C. Encrenaz // WHO Drug Information. - 2006. - P. 199.Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement / D. Sibbing, W. Koch, D. Gebhard, [et al.] // Circulation. - 2010. - Vol. 121, N 4. - P. 512-518.Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement / D. Sibbing, W. Koch, D. Gebhard, [et al.] // Circulation. - 2010. - Vol. 121, N 4. - P. 512-518.Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention / D. Sibbing, J. Stegherr, W. Latz [et al.] / Eur. Heart J. - 2009. - Vol. 30, N 8. - P. 916-922.Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention / D. Sibbing, J. Stegherr, W. Latz [et al.] / Eur. Heart J. - 2009. - Vol. 30, N 8. - P. 916-922.Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents / D. Trenk, W. Hoch-holzer, M.F. Fromm [et al.] // J. Am. Coll. Cardiol. -2008. - Vol. 51, N 20. - P. 1925-1934.Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents / D. Trenk, W. Hoch-holzer, M.F. Fromm [et al.] // J. Am. Coll. Cardiol. -2008. - Vol. 51, N 20. - P. 1925-1934.Davi G., Patrono C. Platelet activation and ath-erothrombosis // N. Engl. J. Med. - 2007. - Vol. 357, N 24. - P. 2482-2494.Davi G., Patrono C. Platelet activation and ath-erothrombosis // N. Engl. J. Med. - 2007. - Vol. 357, N 24. - P. 2482-2494.Effect of clopidogrel added to aspirin in patients with atrial fibrillation / S.J. Connolly, J. Pogue, R.G. Hart [et al.] // N. Engl. J. Med. - 2009. -Vol. 360, N 20. - P. 2066-2078.Effect of clopidogrel added to aspirin in patients with atrial fibrillation / S.J. Connolly, J. Pogue, R.G. Hart [et al.] // N. Engl. J. Med. - 2009. -Vol. 360, N 20. - P. 2066-2078.Fromm M.F. The influence of MDR1 polymorphisms on P-glycoprotein expression and function in humans // Adv. Drug. Deliv. Rev. - 2002. - Vol. 54, N 10. - P. 1295-1310.Fromm M.F. The influence of MDR1 polymorphisms on P-glycoprotein expression and function in humans // Adv. Drug. Deliv. Rev. - 2002. - Vol. 54, N 10. - P. 1295-1310.Fuster V. Fine-tuning therapy for acute coronary syndromes // N. Engl. J. Med. - 2010. -Vol. 363, N 10. - P. 976-977.Fuster V. Fine-tuning therapy for acute coronary syndromes // N. Engl. J. Med. - 2010. -Vol. 363, N 10. - P. 976-977.Genetic determinants of response to clopidogrel and cardiovascular events / T. Simon, C. Verstuyft, M. Mary-Krause [et al.] // N. Engl. J. Med. - 2009. -Vol. 360, N 4. - P. 363-375.Genetic determinants of response to clopidogrel and cardiovascular events / T. Simon, C. Verstuyft, M. Mary-Krause [et al.] // N. Engl. J. Med. - 2009. -Vol. 360, N 4. - P. 363-375.Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopi-dogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis / J.L. Mega, S.L. Mega, S.D. Wiviott [et al.] // Lancet. - 2010. - Vol. 376, N 9749. - P. 1312-1319.Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopi-dogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis / J.L. Mega, S.L. Mega, S.D. Wiviott [et al.] // Lancet. - 2010. - Vol. 376, N 9749. - P. 1312-1319.Pisters R., Dinh T., Crijns H.J. Clopidogrel plus aspirin in atrial fibrillation // N. Engl. J. Med. - 2009. - Vol. 361, N 13. - P. 1312.Pisters R., Dinh T., Crijns H.J. Clopidogrel plus aspirin in atrial fibrillation // N. Engl. J. Med. - 2009. - Vol. 361, N 13. - P. 1312.Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives / D.J. Angiolillo, A. Fernandez-Ortiz, E. Bernardo [et al.] // J. Am. Coll. Cardiol. -2007. - Vol. 49, N 14. - P. 1505-1516.Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives / D.J. Angiolillo, A. Fernandez-Ortiz, E. Bernardo [et al.] // J. Am. Coll. Cardiol. -2007. - Vol. 49, N 14. - P. 1505-1516.Variability in platelet responsiveness to clopidogrel among 544 individuals / V.L. Serebruany, S.R. Steinhubl, P.B. Berger [et al.] // J. Am. Coll. Cardiol. - 2005. - Vol. 45, N 2. - P. 246-251.Variability in platelet responsiveness to clopidogrel among 544 individuals / V.L. Serebruany, S.R. Steinhubl, P.B. Berger [et al.] // J. Am. Coll. Cardiol. - 2005. - Vol. 45, N 2. - P. 246-251.

The authors declare that there are no conflicts of interest present.